Polycystic Ovary Syndrome Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2028

 

A polycystic ovary syndrome is a group of symptoms that include insulin sensitivity, menstrual irregularities, infertility, acne, and excess body and facial hair. It is caused by increased levels of male hormones, or androgens, in females of childbearing age.

The global polycystic ovary syndrome drugs market is expanding due to the disease's increasing prevalence and increased patient awareness. People's increasing purchasing power and increased awareness of PCOS are expected to drive growth in the global PCOS drugs market.

The need for effective management of Polycystic Ovary Syndrome Treatment Market diseases such as hirsutism, obesity, and infertility is expected to drive up demand for PCOS drugs. In addition, the rising popularity of combination drugs and their increased patient adoption is expected to drive revenue growth in the PCOS drugs market in the coming years.

Rising R&D spending and the introduction of novel drugs are also expected to drive growth in the global polycystic ovary syndrome drugs market over the forecast period. However, a lack of FDA-approved drugs, a low level of awareness of the Polycystic Ovary Syndrome Treatment Market  in developing countries, and rising side effects associated with generics may stymie market growth during the forecast period.

The global market for Polycystic Ovary Syndrome Treatment Market  drugs offers several opportunities for market participants to expand. There is good growth potential in emerging markets, and pharmaceutical drug manufacturers are focusing on emerging economies in Asia Pacific and Africa, such as Kenya and Nigeria, to target a large patient population. Furthermore, effective reimbursement policies and lower drug costs for PCOS treatment are likely to increase PCOS drug adoption globally.

Leading market players are also investing heavily in the development of new branded drugs to treat PCOS, owing to an expected large increase in the global patient population. During the forecast period, demand for branded PCOS drugs is expected to rise significantly.

Key Players

Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., and Crinetics Pharmaceuticals, Inc. are major players in the global polycystic ovary syndrome treatment market.